2. Academic Validation
  3. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

  • Oncotarget. 2016 Jul 19;7(29):45562-45574. doi: 10.18632/oncotarget.10037.
Feiyang Liu 1 2,  Beilei Wang 1 3,  Qiang Wang 1 3,  Ziping Qi 1 3,  Cheng Chen 1 3,  Lu-Lu Kong 4,  Ji-Yun Chen 4,  Xiaochuan Liu 1 5,  Aoli Wang 1 2,  Chen Hu 1 2,  Wenchao Wang 1 3,  Huiping Wang 6 7,  Fan Wu 6 7,  Yanjie Ruan 6 7,  Shuang Qi 1 3,  Juan Liu 1 2,  Fengming Zou 1 3,  Zhenquan Hu 1 3,  Wei Wang 1 3,  Li Wang 1 3,  Shanchun Zhang 3 8,  Cai-Hong Yun 4,  Zhimin Zhai 6 7,  Jing Liu 1 3,  Qingsong Liu 1 2 3
Affiliations

Affiliations

  • 1 High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei 230031, Anhui, P. R. China.
  • 2 University of Science and Technology of China, Anhui, Hefei, 230036, P. R. China.
  • 3 CHMFL-HCMTC Target Therapy Joint Laboratory, Hefei, Anhui, 230031, P. R. China.
  • 4 Institute of Systems Biomedicine, Department of Biophysics, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, P.R. China.
  • 5 Department of Chemistry, University of Science and Technology of China, Anhui, Hefei, 230036, P. R. China.
  • 6 Department of Hematology, The Second Hospital of Anhui Medical University, Hefei, Anhui, 230601, P. R. China.
  • 7 Hematology Research Center, Anhui Medical University, Hefei, Anhui 230601, P. R. China.
  • 8 Hefei Cosource Medicine Technology Co. Ltd., Hefei, 230031, Anhui, P. R. China.
PMID: 27322145 DOI: 10.18632/oncotarget.10037
Abstract

BCR gene fused ABL kinase is the critical driving force for the Philadelphia Chromosome positive (Ph+) Chronic Myeloid Leukemia (CML) and has been extensively explored as a drug target. With a structure-based drug design approach we have discovered a novel inhibitor CHMFL-074, that potently inhibits both the native and a variety of clinically emerged mutants of Bcr-Abl kinase. The X-ray crystal structure of CHMFL-074 in complex with ABL1 kinase (PDB ID: 5HU9) revealed a typical type II binding mode (DFG-out) but relatively rare hinge binding. Kinome wide selectivity profiling demonstrated that CHMFL-074 bore a high selectivity (S score(1) = 0.03) and potently inhibited ABL1 kinase (IC50: 24 nM) and PDGFR α/β (IC50: 71 nM and 88 nM). CHMFL-074 displayed strong anti-proliferative efficacy against BCR-ABL-driven CML cell lines such as K562 (GI50: 56 nM), MEG-01 (GI50: 18 nM) and KU812 (GI50: 57 nM). CHMFL-074 arrested cell cycle into the G0/G1 phase and induced Apoptosis in the Ph+ CML cell lines. In addition, it potently inhibited the CML patient primary cell's proliferation but did not affect the normal bone marrow cells. In the CML cell K562 inoculated xenograft mouse model, oral administration of 100 mg/kg/d of CHMFL-074 achieved a tumor growth inhibition (TGI) of 65% without exhibiting apparent toxicity. As a potential drug candidate for fighting CML, CHMFL-074 is under extensive preclinical safety evaluation now.

Keywords

BCR-ABL; Chronic Myeloid Leukemia; PDGFR; kinase inhibitor.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z